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Abstract
Background: The drug using risk behaviors associated with injection drug
use are a major public health issue due to the increased risk of contracting bloodborne pathogens such as the Hepatitis C Virus (HCV). Needle and syringe sharing
is well established to be an efficient mode of transmission of HCV.

The

prevalence of HCV among injection drug users (IDUs) in Cd. Juarez is
documented to be over 90%. However, the literature on the sexual transmission of
HCV is minimal. Methods: The aim of this cross-sectional pilot study was to
determine the prevalence and correlates of HCV and risk behaviors among IDUs
and their non-injecting sex partners in Cd. Juarez. A mix of convenience sampling
and snowball sampling was used for recruitment.

The outreach workers

interviewed 50 IDUs with their non-injecting sex partners (n=50 couples). The
outreach workers administered a structured interview to assess demographics and
sexual and drug using risk behaviors, conducted the rapid HCV test (OraQuick®
HCV Rapid Antibody Test, OraSure Technologies, Inc.). Participants received an
equivalent of $15 USD for their time. Univariate statistics were conducted for
socio-demographic characteristics, sexual and drug behaviors, other HCV risks,
and HCV status. Bivariate analyses were conducted for self-report sexual risk
behaviors among the non-injecting sex partners by HCV status using Fisher Exact
Tests. A p-value <0.05 was considered to be statistically significant. Among the
non-injecting sex partners, sex while under the influence of drugs or alcohol,
unprotected vaginal or anal penile sex, traumatic anal sex, and having concurrent
sexual partners were the exposure variables with HCV status as the outcome
variable.

Results: Among the IDUs and non-injecting sex partners, HCV

prevalence was 96% and 18.4%, respectively. Those non-injecting sex partners
who were HCV reactive also had IDU sex partners who were HCV reactive.
vi

Among those non-injecting sex partners who reported having sex, 42.9% of HCV
reactive and 21.6% of HCV non-reactive reported having used drugs before,
during, or after sex. This was not statistically significantly different based on the
Fisher Exact Test (p=0.341).

Among those non-injecting sex partners who

reported having sex, 55.6% of HCV reactive and 80.0% of HCV non-reactive
reported having used drugs before, during, or after sex, which was not statistically
significantly different (Fisher Exact Test p=0.195). One non-injecting sex partner
reported having traumatic anal sex and was HCV non-reactive. Among those noninjecting sex partners who reported having sex, 42.9% of HCV reactive and 8.1%
of HCV reactive reported having concurrent sexual partners, which was
statistically significantly different (Fisher Exact Test p=0.042). Conclusion: The
findings suggested having concurrent sexual partners was associated with HCV
reactivity. Future HCV prevention efforts (e.g., condom distribution, education)
should include the sex partners of IDUs.
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Chapter 1: Background and Significance
Needle and syringe sharing is well documented to be a mode of transmission of bloodborne pathogens such as Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)
(Baumbach, et al., 2008; Betteridge, Jurgens, & T., 2008; Bollepalli, et al., 2007; Cavalheiro, de
La Rosa, Elagin, Tengan, & Barone, 2010; Daniels, 2009; Hand & Vasquez, 2005; Kwon,
Iversen, Maher, Law, & Wilson, 2009; Lorentz, Hill, & Samimi, 2000; Reyes, et al., 2006).
However, the prevalence of the sexual transmission of HCV is minimal with studies reporting
conflicting results (Alary, et al., 2005; Schmidt, et al., 2011; N. Terrault, 2002). The high-risk
behaviors associated with injection drug use are a major public health issue to the risk for the
transmission of HCV (Daniels, 2009; WHO, 2003). Further, of those who are infected with
HCV, 50% do not know they are infected (CDC, 2010). As a consequence, people may
unknowingly be infecting others and thus, facilitating the spread of the disease (CDC, 2010).
1.1

HEPATITIS C VIRUS
Hepatitis is a general term used to indicate inflammation in the liver that can be caused

by numerous agents such as viruses, alcohol abuse, and medications (WHO, 2003). The most
common types of hepatitis are Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), and HCV
(Daniels, 2009). Acute viral hepatitis is caused by three distinct viruses with different modes of
transmission. For example, HAV develops and incubates in the liver approximately over 28 days
and the virus is shed through excrements (CDC, 2010). Consequently, the primary mode of
transmission is fecal-oral route and food or water contaminated by feces (CDC, 2010). Like
HAV, HBV develops and incubates in the liver over an average of 90 days after exposure (CDC,
2012). The primary mode of transmission is through infected body fluids to include blood,
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semen, and saliva coming in contact with broken skin or the moist lining in the body (CDC,
2012) Both HAV and HBV have safe and effective treatment and vaccines. However, no
vaccine is available for HCV due to the constant mutation and various genotypes (Abrignani,
Houghton, & Hsu, 1999; Prince & Shata, 2001). HCV is primarily transmitted from blood
exposure through the disruption of the skin integrity (AASLD, 2012). The average incubation
period between the time of exposure to seroconversion is eight to nine week.
HCV is in the Flavivirdae family and is a spherical, enveloped, ribonucleic acid (RNA)
virus that has a positive, single-stranded virus with 6 genotypes and several subtypes (JimenezMendez, Uribe-Salas, Lopez-Guillen, Cisneros-Garza, & Castaneda-Hernandez, 2010),(SantosLopez, Sosa-Jurado, Vallejo-Ruiz, Melendez-Mena, & Reyes-Leyva, 2008). The most common
genotype in Mexico (70.3%) and the U.S. (72%) is genotype 1 (McHutchison, et al., 1998;
Santos-Lopez, et al., 2008). The genotype 1 is associated with a more rapid disease progression
and more resistant to current drug therapy (Santos-Lopez, et al., 2008). According to the
American Association for the Study of Liver Disease (AASLD) clinical practice guidelines, the
gold standard treatment for HCV is a combination of peginterferon (PegIFN) and ribavirin
(RBV) for 48 weeks (Ghany, Nelson, Strader, Thomas, & Seeff, 2011). If a person has HCV
genotype 1, then a direct-acting antiviral drug such as boceprevir and telaprevir is added to the
gold standard treatment (Ghany, et al., 2011). Generally, the drugs are taken three times a day for
48 weeks and dosed according to how far the disease has progressed, existing co-morbidities,
and treatment preference of patient (Chou, Clark, & Helfand, 2004; Ghany, et al., 2011). The
goal of the treatment is to slow or stop the progression of HCV toward cirrhosis and
hepatocellular carcinoma (Wilkins, Malcolm, Raina, & Schade, 2010).
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HCV infection is often asymptomatic with more than 90% of the cases exhibiting no
symptoms or mild symptoms after initial infection (AASLD, 2012). An infected person maybe
infected for 10 to 50 years before symptoms such as malaise, vague abdominal discomfort,
nausea and vomiting which are too general to be attributed to HCV infection (Heymann, 2004).
Due to the insidious nature of symptoms, those infected often go undetected and untreated with
2% to 25% developing cirrhosis, hepatocellular carcinoma, and end-stage liver disease (LelutiuWeinberger, et al., 2009). As the most common blood-borne illness in the U.S., HCV leads
mortality among the drug using community and liver disease patients and is the leading
indication of liver transplants in the U.S. (AASLD, 2012; HRC, 2010; Iversen, Wand,
Gonnermann, Maher, & Programs, 2010; TDSHS, 2010).
The World Health Organization (WHO) estimates HCV infects 130-170 million people
or approximately 3% of the global population (WHO, 2003). Although the general prevalence
rate in Mexico (1.6%) is lower than Latin America (1.7%), a prevalence study of HCV reported
in Cd. Juarez that 98.7% of IDUs were HCV positive in comparison to El Paso and Las Cruces at
76.4%, and 80%, respectively (Baumbach, et al., 2008).
1.2

RISK FACTORS
Several risk factors have been identified and established to increase the chances of HCV.

The risk factors are as follows: prior blood or organ transplant before July 1992, children born to
HCV infected mothers, people who have had needle stick injuries from HCV infected blood, and
injection drug use (AASLD, 2012). Along the U.S.-Mexico border, tattooing in unsterilized
conditions and by unlicensed professionals, rather than in commercial establishments, was found
to be an independent risk factors for HCV infection among inmates in prisons/jails and gang
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members or friends at home (Hand & Vasquez, 2005).

The average length of time from

exposure to seroconversion is eight to nine weeks (CDC, 2006).
HCV transmission via needle and syringe sharing has been well documented (Baumbach,
et al., 2008; Betteridge, et al., 2008; Bollepalli, et al., 2007; Cavalheiro, et al., 2010; Daniels,
2009; Hand & Vasquez, 2005; Kwon, et al., 2009; Lorentz, et al., 2000; Reyes, et al., 2006). For
example, in a study conducted in Puerto Rico, the researchers reported that among IDUs who
had been injecting for less than one year, 75% were found to be HCV positive (Reyes, et al.,
2006). As a result of the wealth of literature regarding injection drug use and HCV, legal needle
and syringe exchange programs have been established in Mexico and in the United States (Kaiser
Family Foundation, 2011; Scholl & Nicholson, 2010). However, the prevalence and correlates
of the sexual transmission of HCV is minimal. Some studies have noted sexual risk behaviors
associated with HCV (Bollepalli, et al., 2007; Cavalheiro, et al., 2010; Leruez-Ville, Kunstmann,
De Almeida, Rouzioux, & Chaix, 2000; Nowicki, et al., 2005; Santos-Lopez, et al., 2008;
Schmidt, et al., 2011; Wilkins, et al., 2010) whereas other studies have reported conflicting
results and have shown no correlation between the sexual risk factors and HCV infection (Alary,
et al., 2005; Bollepalli, et al., 2007; Daniels, 2009; Osella, et al., 1998; Reyes, et al., 2006).
The sexual transmission of HCV is plausible, but less efficient when compared to other
blood borne diseases such as HBV and HIV (Nowicki, et al., 2005). Studies have suggested the
presence of HCV RNA in the genital tracks of men and women that makes female-to-male,
male-to-female, female-to-female, and lastly male-to-male transmission possible (Bollepalli, et
al., 2007; Leruez-Ville, et al., 2000; Manavi, et al., 2002; Nowicki, et al., 2005).
Some studies have suggested that certain sexual behaviors are associated with HCV
reactivity (Schmidt, et al., 2011; Terrault, 2002). For example, a case-control study conducted in
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Germany by Schmidt et al. (2011) among HIV positive men who have sex with men (MSM) that
participated in risky sexual behaviors such as frequent rectal trauma with bleeding, frequent
receptive fisting without gloves, group sex, and consumption of nasally administered drugs was
associated HCV reactivity (Schmidt, et al., 2011). Further, the study noted blood exposure during
sex rather than seminal fluid could have contributed to their HCV status (Schmidt, et al., 2011).
In another study, nine heterosexual couples were followed over three years in a prospective
study. The study concluded that male-to-female transmission was possible if the moist lining of
the genital tract was broken, which increased the risk of transmission (Cavalheiro, et al., 2010).
In contrast to the aforementioned studies, Alary et al. (2005) conducted a prospective
cohort study of MSM in Canada. The study did not find a statistical significance associating
sexual behaviors with HCV status after controlling for injection drug use (Alary, et al., 2005). In
a separate study conducted in Argentina, Osella et al. found no association between sexual risk
behaviors and HCV positivity among MSM (Osella, et al., 1998).
1.3

CD. JUAREZ, MEXICO
The 2,000-mile U.S.-Mexico border is one of the busiest international borders in the

world (Weinberg, et al., 2003). The Paso del Norte region represents the midpoint of the this
extensive border and is comprised of Cd. Juarez, El Paso, Texas, and Las Cruces, New Mexico.
It is home to one of the busiest border crossings in the U.S. (RITA, 2012).

The rugged

mountains, wide-open deserts, and numerous canyons coexist with improved and wellmaintained roadways. The area is an ideal environment for narcotraficantes to store drugs until
shipment (Campbell, 2011). Drug traffickers use many of the connections such as the
international bridges, railroad crossing, and tunnels between El Paso and Cd. Juarez to their
advantage (Campbell, 2011). As a result, the southwest border is established as a High Intensity
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Drug Trafficking Area (HIDTA) for past 20 years which is determined by harmful impact of
drugs as well as the production, manufacturing, importation, and distribution of illicit drugs
(ONDCP, 2012).
Historical events in the Paso del Norte region have facilitated a drug culture that spans
generations (Ruiz, 1998). For example, during prohibition policies governing drugs and alcohol
caused an increase in drug prices in the U.S. and thus, made opium production and trafficking
lucrative in Mexico (Bucardo, et al., 2005). Simultaneously, two international bridges were built
to encourage tourism in Cd. Juarez (Ruiz, 1998). Entrepreneurs capitalized on the construction
by moving drugs into the U.S. across these bridges (Bucardo, et al., 2005). As road systems
improved under North American Free Trade Agreement (NAFTA), the border region saw a rapid
growth in their economy and industrialization that facilitated drug trafficking in particular heroin
and cocaine (CONADIC, 1998; Kaplan & Valdez, 2007; West Texas High Intensity Drug
Trafficking Area Drug Market Analysis, 2009).
Cd. Juarez and El Paso are on the cusp of a legal divide where El Paso criminalizes
possession of needles and syringes whereas Cd. Juarez has legalized it (Chang, 2011; Magee,
2008). However, a qualitative study concluded actions by Mexican law enforcement are not
consistent with the law, which has led to arrests and physical violence of IDUs for possession of
syringes (Miller, et al., 2008). A physical border divides Texas and Cd. Juarez, but social
realities such as illicit drug use are mobile and blur the lines of this legal divide (Ruiz, 1998).
Although the region shares the same language and culture, the policies and resources are
dependent upon location making Cd. Juarez a unique site for research (Ramos, et al., 2009). In
addition, the increasing violence in Cd. Juarez is changing the context in which IDUs are using
and making them vulnerable to unsafe drug behaviors such as injecting with used needles
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(Baumbach, et al., 2008; Miller, et al., 2008). Therefore, the study laid the framework to
understand individual behaviors in the context of aggressive policing practices and increasingly
violent city, which could be contributing to increased risk of infection (Miller, et al., 2008;
Strathdee, et al., 2011).
1.4

POPULATION OF CD. JUAREZ
The border state of Chihuahua is a common destination for migration (Ojeda, et al.,

2012). The Paso del Norte region has an estimated population of 2-million people with about 1.3
million living in Cd. Juarez (INEGI, 2012). Those from Cd. Juarez, 32% of them have migrated
from other regions in Mexico (INEGI, 2011). The region has more than 130,000 daily Cd.
Juarez-El Paso border crossings with the highest number of personal vehicles and pedestrian
crossings in Texas (Border Crossings, 2011).
The transient nature of Cd. Juarez residents has historical significance that adds to the
complexity of these inhabitants. In 1964, the bracero program was created to fill a void left
behind by young men drafted during World War II. This allowed Mexican laborers to work
legally in the U.S. agribusiness and ultimately, attracted thousands of migrants to the border
(Lorey, 1999; Ruiz, 1998). After disbanding the Bracero Program, thousands of displaced
Mexicans were sent to Cd. Juarez to repatriate with no resources or means to return home (Ruiz,
1998). To ease the burden of unemployment and congestion, the Border Industrialization
Program (BIP) was created, which led to the rise of the maquilas (Ruiz, 1998). Maquilas are
foreign assembly plants on the Mexican side of the border that turn raw goods into finished
products (Ruiz, 1998).
The creation of the maquila program in tandem with NAFTA attracted people from all
over Mexico seeking employment (Kaplan & Valdez, 2007; Ruiz, 1998). The influx of migrants
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outnumbered the jobs available in the maquila (Ruiz, 1998). Although the maquilas pay above
minimum wage, the cost of living along the Mexican side of the border is higher than the interior
(Ruiz, 1998). Thus, a large population of people with little to no money had no social ties to Cd.
Juarez making them vulnerable to substance abuse and narcotraficantes (Kaplan & Valdez,
2007; Ruiz, 1998).
Although Mexico has a history of the drug production and trafficking, over the last 10
years illicit drug use in Mexico has increased and become a recognizable problem (Bucardo, et
al., 2005). Factors that could be contributing to the illicit drug use are increased border security
along the U.S.-Mexico border, low street prices of black tar heroin, and a down economy
(Bucardo, et al., 2005). In Mexico, Cd. Juarez ranks 2nd nationally in drug consumption behind
Cd. Tijuana with approximately 6,000 injection drug users (IDU) and as many as 186 picaderos
(drug injecting locations) (Cravioto, Medina-Mora, de la Rosa, Galvan, & Tapia-Conyer, 2003).
The drug prevalence of Cd. Juarez among adults having ever used illicit drugs is documented to
be 9.2%, which is almost twice the national average of 5.3% (CONADIC, 1998). In 2010, the
past month use of illicit drugs over than 12 years old was 8.9% (SAMHSA, 2011). Among
88,452 admissions to treatment programs in 2007 funded by the Texas Department of State
Health Services (DSHS), 26% reported a history of injection drug use (Maxwell, 2008).
Previous studies conducted in Cd. Juarez focused on HIV and STI transmission and
further, have not studied HCV among sex partners of IDU, which highlights a gap in literature
(Ferreira-Pinto & Ramos, 1995; Garcia, Yam, & Firestone, 2006; Strathdee, et al., 2011; White,
et al., 2007; Zhao, Ashery, Wild, & Young, 1996).
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Chapter 2: Study Aims and Hypotheses
2.1

GOAL AND OBJECTIVES
The primary goal of this cross-sectional, pilot study was to identify risk behaviors

associated with HCV reactivity in order to decrease the negative impact injection drug use has on
social networks of IDUs. Due to the minimal literature on the sexual transmission of HCV, the
objective was to update the descriptive and analytical epidemiology of HCV. In addition, points
of intervention for partners can be incorporated into harm reduction programs. The goal was
achieved through the following aims.
2.2

AIMS

Aim 1: To estimate the prevalence of HCV infection among IDUs and their non-injecting sex
partners
Aim 2: To estimate the prevalence of injection drug using risk behaviors associated with HCV
reactivity among IDUs
Aim 3: To identify the risk factors correlated to HCV status among non-injecting sex partners
Aim 4: To estimate the prevalence of sexual risk behaviors associated with HCV reactivity
among non-injecting sex partners
2.3

HYPOTHESIS

Hypothesis 1: Among non-injecting sex partners, sex under the influence (e.g., alcohol or drug
use before or during they had sex) is associated with HCV reactivity.
Hypothesis 2: Among non-injecting sex partners, unprotected vaginal or anal penile sex (e.g.,
condom) is associated with HCV reactivity.
Hypothesis 3: Among non-injecting sex partners, traumatic anal sex is associated with HCV
reactivity.
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Hypothesis 4: Among non-injecting sex partners, having concurrent sexual partners is associated
with HCV reactivity.
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Chapter 3: Methods and Materials
3.1

STUDY PARTICIPANTS
The participant sample included IDUs and their non-injecting sex partners.

The

eligibility criteria for all participants included: (a) being age 18 years or older; (b) having
vaginal, oral, or anal sex with each other two months ago or prior; (c) providing informed
consent; and (d) self-report refrain from drugs and alcohol at least one hour prior to signing the
informed consent. The “two months ago or prior” window was utilized to allow seroconversion
from the point of exposure, which was vaginal, oral, or anal sex (See Figure 1). Specific
eligibility criteria for IDU clients included injection drug use in the last 30 days. Specific
eligibility criteria for the non-injecting sex partner is having never injected drugs in their
lifetime. The exclusion criteria included: (a) inability or unwillingness to provide informed
consent due to being under the influence of drugs and/or alcohol at the time of the recruitment
into the study; (b) not refraining from drugs and alcohol one hour prior to signing the informed
consent; and (c) anyone who does not meet the inclusion criteria.
Participants were recruited during HIV street outreach programs such as condom
distribution and needle exchanges. Prior to signing the informed consent, the outreach workers
conducted a short, 5-minute printed presentation on the consent form that contains text and
pictorials. The information included: the purpose of the study, what is involved in the study (e.g.,
face-to-face interview, finger stick for blood), potential risks and discomforts, what will happen
if they become injured, benefits in participation, receiving monetary compensation, right to
withdrawal from the study, contact information of investigators, and the voluntary and
confidential nature of their participation. This method has been shown to be effective in
increasing consent preparedness, understanding the study involvement, and confidence in
11

making an informed and appropriate decision and thereby minimizing coercion (C. B. Fisher,
2010).
3.2

SAMPLE SIZE
The target sample size was 50 IDUs with their non-injecting sex partners (N=50 couples).

3.3

STUDY DESIGN
This was a cross-sectional, pilot study to determine the prevalence and correlates of HCV

and risk behaviors among IDUs and their non-injecting sex partners in Cd. Juarez. Local
outreach workers recruited participants during HIV street outreach programs using a mix of
convenience sampling and snowball sampling.

The research study was approved by the

University of Texas at El Paso and Mexico Institutional Review Board (See Figure 3 and 4).
3.4

MEASURES
In 1993, the Community Work Group at NIDA and the AIDS Cooperative Agreement

Program created the Risk Behavior Assessment (RBA) questionnaire as a means of assessing
HIV risk behaviors (NIDA, 1993). Recently, the Center of Interdisciplinary Research on AIDS
from Yale University updated the RBA by adding more questions on drug risk factors to
HIV/AIDS (Heimer, Grau, Curtin, Khoshnood, & Singer, 2007). The RBA had shown reliability
in drug use behaviors, income, incarceration, and hepatitis.(D. G. Fisher, Johnson, & Reynolds,
1999; D. G. Fisher, Kuhrt-Hunstiger, Orr, & Davis, 1999; D. G. Fisher, et al., 1993; Johnson,
Fisher, & Reynolds, 1999; Needle, et al., 1995; Paschane, Fisher, Cagle, & Fenaughty, 1998)
Native Mexican Spanish speakers translated the RBA. Three couples were recruited to pilot test
the questionnaire to ensure proper street drug language, sequence of questions, and skip patterns.
Changes on the questionnaire were made based off the recommendations of the outreach workers
and participants.
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One of the eligibility criteria for both participants was to have had sex for more than two
months, which would allow time for seroconversion from the point of exposure. However, to
decrease recall bias, the questionnaire covered drug using and sexual risk behaviors in the last 30
days. The questionnaire measured areas of socio-demographic characteristics; non-injecting
drug use behaviors; sexual risk behaviors between IDUs and their non-injecting sex partners;
other HCV risks; injection drug use behaviors; sexual health; and HCV status.
3.4.1

Socio-Demographic Characteristics
Socio-demographic characteristics in the demographic section assessed were age, gender,

ethnicity, highest education attained, marital status, and income.
3.4.2

Drug Using Behaviors
All participants were asked about their drug using practices and behaviors. Questions

regarding non-injection drug use included type of drug used. The drugs assessed included
alcohol, marijuana, heroin, methamphetamine, crack/cocaine, methadone with and without a
prescription, analgesics (e.g., morphine, Percocet) without a prescription, sedatives (e.g., Valium,
Xanax), and inhalants (e.g., agua celeste) alone and in combination.
3.4.3

Sexual Risk Behaviors
The sexual risk behaviors between the IDUs and their non-injecting sex partner were

assessed. The questions covered sexual behaviors and assessed the relationship between the IDU
and the non-injecting sex partner; sex under the influence; type of substance used before or
during sex; transactional sex; history of sexually transmitted infections (STIs); receptive anal
sex; unprotected vaginal or anal penile sex; traumatic anal sex leading to pain and/or bleeding;
and having concurrent sexual partners. Concurrent sexual partners was defined as having two or
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more sexual partners that overlap in time (USAID, 2011). To decrease recall bias, the set
timeframe for concurrent sexual partnerships was in the last 30 days.
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3.4.4

Other HCV Risks
Other HCV risks that have been documented in the literature were measured. Ever

having been arrested, injection drug using behaviors the IDUs may engaged in while
incarcerated, history of tattoos, piercings, blood transfusions, and organ transplant were also
measured.
3.4.5

Injection Drug Using Risk Behaviors
The injection drug using risk behaviors assessed included identifying the most common

drug(s) injected; most common form of syringe acquisition; most common locations to inject;
having injection partners; and receptive drug sharing. Under receptive drug sharing, measures
included splitting drugs in liquid form; using a syringe after someone else had used it; cleaning
the syringe with bleach before injecting; using the same works after someone else had used it;
and using the same liquids to flush the syringe.
3.4.6

HCV Blood Test Status
The OraQuick® measures the HCV blood status (e.g., reactive, nonreactive, and invalid)

based on the fingerstick blood test. If a test was found to be invalid, then the recommendations
were to repeat the test with a new testing kit. OraQuick® HCV Rapid Antibody Test was
approved on February 2011 by the U.S. Food and Drug Administration (FDA) (FDA, 2011). The
sensitivity (true positive results) and specificity (true negative results) among those exhibiting
symptoms, no symptoms, and at risk populations were 99.5% and 99%, respectively (FDA,
2011). The OraQuick has been evaluated with interfering substances and medical conditions and
none have had an impact on the detection on assay performance (FDA, 2011). No adverse
effects have been associated with the OraQuick HCV test (FDA, 2011).
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3.5

DATA COLLECTION
Programa Compañeros, A.C. has over 25 years of experience working with hidden

populations.

Key informants and outreach workers recruited participants using a mix of

snowball sampling and convenience sampling during ongoing HIV outreach programs. Their
expertise was an invaluable asset to the approach of recruiting and identifying participants that
brought a better understanding to the factors mediating HCV infection. Outreach workers were
trained in questionnaire administration and the collection of blood samples via a fingerstick
using the OraQuick® HCV Rapid Antibody Test. All meetings and training between the UTEP
team and the outreach workers were conducted via video teleconferencing prior to the start of
data collection.
Data collection consisted of a structured, face-to-face administered, a HCV and HIV
blood test, pre/post testing and harm reduction counseling, all which lasted approximately 90
minutes. The questionnaire itself lasted approximately 45 minutes. Each question was read
aloud by the interviewer in Spanish. Data collection took place in the field during ongoing HIV
outreach efforts.
Programa Compañeros, A.C. trained staff in sequence (1) assessed eligibility; (2)
conducted a short, five minute printed presentation on the informed consent; (3) obtained a
signature on the informed consent; (4) conducted a one time only fingerstick for the HCV rapid
test (OraQuick® HCV Rapid Antibody Text, OraSure Technologies, Inc.) and Rapid HIV
(OraQuick® ADVANCE® Rapid HIV-1/2 Antibody Test, OraSure Technologies, Inc.); (5)
conducted the structured, face-to-face interview; and (6) counseled in harm reduction. HCV
reactive participants were referred to the Center for HIV and STI Prevention and Treatment
[Centro Ambulatorio de Prevención y Atención en SIDA e ITS] (CAPASITS). All participants
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received an equivalent of $15 USD compensation for their time. Figure 2 illustrates the data
collection process of the study.
At no point did UTEP faculty or students travel to Cd. Juarez for research purposes. Data
collected were delivered to UTEP from Programa Compañeros, A.C. on a weekly basis via
courier.
3.6

DATA ANALYSIS

3.6.1

Database Management
Data collected were entered into SPSS version 19.0 and variables were cleaned using

syntax. Missing values were coded as -9 and excluded form analysis. For all the variables, if the
non-injecting sex partner did not have sex in the last 30 days, they skipped questions that were
not applicable. Not applicable was coded as -8. For the analysis, those coded as -8 were coded
“no.” The following variables were created based on participant responses.
Condom Variable
The condom variable was created to refer to unprotected vaginal or anal penile sex with
male-female, female-male, and male-male responses to barriers used. Participants who were in a
female-female relationship were included in the analysis. However, this combination was coded
as “no” to having unprotected vaginal or anal penile sex. Non-injecting sex partners who
answered “never,” “sometimes,” “half the time,” and “most of the time” for condom use were
coded as “no.” Those who answered “always” to condom use were coded as “yes.”
Traumatic Anal Sex Variable
A variable for traumatic anal sex leading to bleeding was created and defined as having
pain in or around the anus or visual signs of blood coming from anus after anal sex. The
traumatic anal sex variable was created by combining four variables on the signs and symptoms
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of trauma. Those who responded “yes” to interior pain of the anus during or after sex; external
pain or pain upon touching the anus; blood from the anus; and tearing in or near the anus were
coded “yes” for traumatic anal sex. All others were coded “no.” Participants were asked
(yes/no) if they experienced any of the four signs or symptoms during anal sex. If the participant
did not experience pain, then they were coded as no pain.
3.6.2 Statistical Analysis
Univariate statistics were provided for measures assessed from the IDU and their noninjecting sex partners including mean and standard deviation for continuous variables and
frequency and percent for categorical variables. Bivariate associations between HCV reactivity
and risk behaviors in the last 30 days among non-injecting sex partners were determined using
Fisher Exact Tests. A p-value<0.05 was considered to be statistically significant.
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Chapter 4: Results
4.1

UNIVARIATE RESULTS

4.1.1

Characteristics of the Sample
Fifty-one couples were enrolled and two were excluded from analysis. The first couple

was excluded after it was discovered the non-injecting sex partner was less than 18 years old.
The second couple was excluded due to pending blood HCV results. As a result, 49 couples
were analyzed in the study.
4.1.2

Socio-Demographic Characteristics
The socio-demographic characteristics are depicted in Table 1. The mean age of the

IDUs was 37.6 years old. Most IDUs were male (71.4%) of Mexican descent and most had at
least a secondary school education (93.9%) and were married. Most of the IDUs made between
101- 250 pesos. The mean age of the non-injecting sex partners was 41.8 years old. Most were
female (71.4%) of Mexican descent (98%) and most have at least a secondary school education
(87.7%) and were married (93.9%). Over half (53.1%) of the non-injecting partner earned an
average between 50-150 pesos per day in the last 30 days.
4.1.3

Drug Using Risk Behaviors
About half (40.8%) the IDUs reported alcohol use. The most common drugs consumed

were heroin (98.0%), methadone with prescription (40.8%), and marijuana (38.3%), respectively.
Over half of the non-injecting sex partners reported consuming alcohol (51%). Of the twentyfive of those who reported consuming alcohol, seven (14.3%) reported consuming a substance
other than alcohol. Among the non-injecting sex partners who used a drug, marijuana was the
most common drug (85.7%).
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4.1.4

Sexual Risk Behaviors
All IDUs reported having vaginal, oral, or anal sex in the last 30 days. Most entered the

study with their spouse or stable partner as their non-injecting sex partner (93.9%). Over half
had used alcohol or drugs before or during sex (53%). Twenty-six of the IDUs who had sex
under the influence of alcohol or drugs more than half (53.8%) reported using heroin alone
followed by alcohol (34.6%). Almost a quarter of 49 IDUs (22.4%) had engaged in transactional
sex whereby someone had given them money; drugs; shelter; transportation; alcohol; food; or
other things to have sex with them. Eight IDUs (16.7%) reported having ever had a sexually
transmitted infection (STI). Of all the IDUs, 41 (83.7%) reported having unprotected vaginal or
anal penile sex. None of the IDUs reported having traumatic anal sex. Over a quarter (26.5%)
had concurrent sexual partners.
Forty-four of the non-injecting sex partners reported having sex in the last 30 days. Most
entered the study with their spouse (81.8%). Eleven (25%) reported sex under the influence of
alcohol or drugs with their IDU partners. Eight of 11 (72.7%) consumed alcohol most frequently
during those episodes. Of all the non-injecting sex partners, four reported (8.2%) engaged in
transactional sex whereby someone had given them money, drugs, shelter, transportation,
alcohol, food, or other things to have sex with them. Seven had a history of having ever had an
STI. Among all the non-injecting sex partners, 37 reported unprotected vaginal or anal penile
sex (75.5%) with their IDU sex partner. One non-injecting sex partner reported having traumatic
anal sex and was HCV non-reactive. Six of 49 (13.6%) non-injecting sex partners reported
having concurrent sexual partners.
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4.1.5

Other HCV Risks
Forty-three of the 49 IDUs (87.8%) reported having ever been in jail. More than half

(58.1%) who reported being in jail also reported injecting drugs while being in jail. Almost all
(92.3%) who injected in jail reported sharing needles to inject. Tattoos were common among
IDUs with 85.7% having had tattoos. Twenty (40.8%) of the IDUs reported having piercings.
Only two (4.1%) IDUs and no IDUs reported being transfused blood products (e.g., blood,
plasma) and received an organ donation, respectively.
Almost half (42.9%) of the non-injecting sex partners reported having ever been in jail.
Over half (51%) had tattoos and almost a quarter (24.5%) had piercings. Seven of the 49 noninjecting sex partners reported having ever received blood products and none had received an
organ or tissue transplant.
4.1.6

Injection Drug Using Risk Behaviors
The most common drug they injected was heroin (95.9%) followed by heroin and cocaine

together (4.1%). More than half (61.2%) of the IDUs reported obtaining syringes from a needle
exchange program followed by a pharmacy without a prescription (26.5%). The most common
locations to inject was where the IDU lived (63.3%) and shooting galleries (22.4%). Receptive
drug sharing was prevalent among the IDUs. Thirty-four (69.4%) IDUs reported having an
injection partner. Of the 34 IDUs who have injection partners, 26 (76.5%) split drugs in liquid
form; 22 (64.7%) reported using a syringe after someone else; less than half cleaned their
syringes with bleach before injecting; almost all used the same drug works (e.g., cookers,
spoons, cans, cottons) and same liquids to flush the syringes after someone else had used it
(93.8% and 85.3%).
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4.1.7

HCV Status
Of the 49 IDUs interviewed, 47 (96%) were HCV reactive. Of the 49 non-injecting sex

partners interviewed, 9 (18.4) were HCV reactive.
4.2

BIVARIATE RESULTS
Based on the contingency table, one cell had an expected cell count less than five for sex

under the influence, unprotected vaginal or anal penile sex, and having concurrent sexual
partners. Hence, the Fisher Exact Test was used to determine if there was an association
between them and HCV reactivity.
4.2.1

Sex Under the Influence
Among those non-injecting sex partners who reported having sex, 42.9% were HCV

reactive and 21.6% were HCV non-reactive reported having sex under the influence. This was
not statistically significantly different (Fisher Exact Test p=0.341) (See Table 2).
4.2.2

Unprotected Vaginal or Anal Penile Sex
Among those non-injecting sex partners who reported having sex, 55.6% were HCV

reactive and 80.0% were HCV non-reactive reported having unprotected vaginal or anal penile
sex. This was not statistically significantly different (Fisher Exact Test p=0.195) (See Table 2).
4.2.3

Traumatic Anal Sex
One non-injecting sex partner experienced traumatic anal sex and was HCV non-reactive.

Since only one participant experienced traumatic anal sex, statistical analysis was not conducted.
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4.2.4

Concurrent Sexual Partners
Among those non-injecting sex partners who reported having sex, 42.9% were HCV

reactive and 8.1% were HCV non-reactive reported having concurrent sexual partners. This was
statistically significantly different (Fisher Exact Test p=0.042) (See Table 2).
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Chapter 5: Discussion
This cross-sectional, pilot study aimed to update the descriptive epidemiology of HCV
among IDUs and their non-injecting sex partners. In addition, of the minimal literature on the
sexual transmission of HCV, there have been conflicting studies regarding the correlation of
HCV and sexual behaviors. Therefore, the study also aimed to add to the analytical aspect of
epidemiology by determining the correlates of HCV and risk behaviors among non-injecting sex
partners of IDUs. The four sexual exposure variables tested as correlates to HCV reactivity were
sex while under the influence, unprotected vaginal or anal penile sex, traumatic anal sex, and
having concurrent sexual partners. Of the four variables, having concurrent sexual partners was
the only variable found to be statistically significant with HCV reactivity. This supported the
hypothesis that having concurrent sexual partners was associated with HCV reactivity.
Despite a small sample size, concurrent sexual partners and HCV reactivity was found to
be associated, which suggested concurrent sexual partnership was a strong determinant of HCV
reactivity. The finding was aligned with HIV research studies, which found that concurrent
sexual partners were more like to be HIV-positive than those had had one lifetime partner
(Mishra & Van Assche, 2009; (U.S. AID, 2011). In addition, the association between HCV
reactivity and having concurrent sexual partners had been studied among different populations to
include sex workers, MSM, and those in surveillance studies for STDs and STIs. The varying
rates of HCV reactivity among the groups may indicate differences in sexual risk behaviors such
as frequency or the type of sex (N. Terrault, 2002). In contract, disparities in HCV rates among
the groups could be due to non-sexual experiences such as sharing of drug paraphernalia other
than needles. Therefore, more research is required to determine an association between HCV
reactivity and concurrent sexual partnerships. Regardless, this finding coincided with previous
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research when participants had more lifetime partners increased their overall risk (Kaur, et al.,
1996; N. Terrault, 2002).
Sex while under the influence was hypothesized to be a risk factor for HCV reactivity
since this was previously found shown to be a risk factor for the transmission of HIV (Zule,
Costenbader, Meyer, & Wechsberg, 2007). One study among men in substance abuse treatment
suggested those who engaged in sex while under the influence were more likely to engage in anal
sex, having casual partners, and lack of condom use and thus, making them at risk for HIV
transmission (Calsyn, et al., 2010). In addition, the Calsyn et al. study reported alcohol was the
most common substance during sex under the influence, which is comparable to the current
study (Calsyn, et al., 2010). Despite these earlier finding this study did not show any statistical
significance among those that engage in sexual activity while under the influence.
Unprotected vaginal or anal penile sex was found not to be statistically significant for
HCV reactivity. This may be due to the change from ordinal data to nominal data in the database
management phase. However, the lack of statistical significance was in agreement with other
research that had failed to find a correlation between high-risk sexual behaviors and HCV
reactivity (Alary, et al., 2005; Bollepalli, et al., 2007; Nurutdinova, Abdallah, Bradford, O'Leary,
& Cottler, 2011). Only one non-injecting sex partner had experienced traumatic anal sex and was
found not to be HCV reactive. Their partner who is an IDU was found to be HCV reactive. A
single individual did not allow us to perform any statistical analysis regarding traumatic sex and
HCV reactivity. Thus, this would require further research with larger sample sizes to discern if
any significance exists.
Of the four sexual risk behaviors, having had a concurrent sexual partner in the last 30
days was found to be statistically significantly associated with HCV reactivity. No statistical
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significance for the three remaining sexual risk behaviors and HCV reactivity was in contrast to
the study hypothesis. These finding showed the possibility that certain sexual risk factors (e.g.,
concurrent sexual partnership) can increase the potential for HCV transmission. However, HCV
transmission via sexual contact remains much less likely when compared to injection risk
behaviors such as needle sharing.
5.1

LIMITATIONS
The results of the study should be interpreted with the limitations in mind. The first

limitation is the study design was cross-sectional and is limited to collecting data at one point in
time. Therefore, temporal associations cannot be determined.
The second limitation is the study had a sample size of 49 non-injecting sex partners
since this was a feasibility study. Although there was no statistically significant association for
sex under the influence and unprotected vaginal or anal penile sex, this may be due to the small
sample size.
The third limitation of the study was the use of snowball sampling.

In snowball

sampling, the recruiter identifies potential participants who fit the research criteria and ask them
to refer other potential participants who are considered to be “hard to reach.” The negative
aspect of snowball sampling is the recruitment method may result in a lack of heterogeneity
since the participant may be referring people from their social networks (UNODC, 2004). As a
result of, the recruited population may not be representative of the target population (UNODC,
2004). However, this study had similar socio-demographic characteristics and drug using risk
behaviors, as other studies conducted in Cd. Juarez (Baumbach, et al., 2008; Ramos, et al.,
2009).
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The fourth limitation of the study was social desirability response bias. Questions
regarding sexual and drug using behaviors are vulnerable to conforming to current social norms
and standards in order to avoid criticism (Marlowe & Crowne, 1961). Multiple approaches were
used to decrease the social desirability response bias. For example, the Programa Compañeros
outreach workers were utilized due to their familiarity, trust, and rapport they had formed
through the years of daily interaction with them. Additional examples of approaches used to
decrease social desirability response bias is outlined in the strengths section.
5.2

STRENGTHS
The first strength of the study was a adaptation and application of the Risk Behavior

Assessment (RBA), developed by the National Institute of Drug Abuse (NIDA) questionnaire to
assess HCV risk behaviors. The RBA has been shown to accurately capture self-report drug use
among street-recruited, not-in-treatment injection drug users (Weatherby, et al., 1994).

The

second strength of the study was the use of outreach workers to recruit participants. The
outreach workers are former IDUs who are familiar with high drug use neighborhoods where
IDUs congregate. The outreach workers are also familiar with the drug street language used by
IDUs thereby allowing them to communicate with them easily (UNODC, 2004). The familiarity
of the neighborhoods and language has allowed them to establish rapport, trust, and credibility
among active IDUs (UNODC, 2004; Scholl & Nicholson, 2010). Therefore, their efforts have
allowed them access to shooting galleries and to other drug users that are considered hard to
reach (Scholl & Nicholson, 2010).
The third strength of the study was the use of pictorials and texts in the informed consent
phase of the research. In a cross-sectional study conducted among street drug users, researchers
found that a brief, five-minute lesson using colorful texts and pictures increased consent
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preparedness, increased confidence in making the appropriate decision, and reduced
misconceptions regarding study involvement in HIV vaccine trials (C. B. Fisher, 2010). Further,
participants reported having an increased the belief the researcher would be honest and thus, the
participant was more likely to give truthful answer (C. B. Fisher, 2010). The implementation of
this tool was crucial in ensuring sufficient time and information to the participant to make an
informed decision.
5.3

FUTURE RESEARCH
Future research includes determining the variables independently associated for HCV

reactivity among the non-injecting sex partners of IDUs. Other variables of interest to identify if
associations exist would include transactional sex and the history of STDs and STIs, which
would be accomplished through a self-report survey. Further, recruiting a larger sample size
would assist in determining the correlates of sex while under the influence, unprotected vaginal
or anal penile sex, and traumatic anal sex and HCV reactivity.
5.4

CONCLUSION
The present research reveals that having concurrent sexual partners was associated with

HCV reactivity. The public health implication is to include sex partners of IDUs in harm
reduction and education. By including sex partners of IDUs in counseling, sex partners could
engage in more responsible sexual activities and thus, decrease their overall risk of HCV
transmission. Not actively engaging the sex partners would pose as missed opportunities to
decrease the spread of the disease.
Despite the amount of research on HCV transmission, there has been a paucity of
literature regarding the sexual transmission of HCV as well as conflicting results of these studies.
Due to the lack of definitive research combined with the lack of understanding by sex partners on
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the symptoms of the disease, HCV remains a major public health issue. Until a safe and
effective vaccine is widely available, more research should be conducted to identify points of
intervention for decreasing the spread of HCV among the non-injecting sex partners of IDUs.
Although sexual transmission of HCV is lower than injection drug using behaviors, this area
remains a potential avenue for decreasing HCV transmission and the overall health care costs.
To the best of our knowledge, no research has been published examining the prevalence
and correlates of HCV among sex partners of IDUs in Cd. Juarez. Research on the individual
sexual behaviors in the context of increasing violence in the city would lay the framework for
understanding the sexual transmission of HCV.
5.5

DISSEMINATION
Findings of this research have been reported through a poster presentation at the 2012

U.S.-Mexico Border Drug Issues Conference. Future dissemination of findings includes the II
Congreso Brasileño de Prevención de las Hepatitis Virales in Sao Paulo, which will be presented
in August 2012. In addition, abstracts have been submitted and pending acceptance to the Harm
Reduction Coalition National Conference and the National Hispanic Science Network
Conference for presentation in 2012. In addition, findings from this pilot study will be shared
with not only Programa Compañeros, A.C., but with their clients.
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Figure 1 Eligibility Criteria

Sex and drug using behavior
questions pertain to the last 30
days

2 months ago

30 days

At least two months ago had
vaginal, oral, or anal sex

Now

In the last 30 days, injected
drugs
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Figure 2 Flowchart of the Data Collection Process

UDIs
Entrevistadora: MGZM

Elegibilidad

Elegibilidad

Consentimiento Informado *

Parejas Sexuales
Entrevistadora: MLGB

Consentimiento Informado *

Son elegibles de participante y pareja

Pre-Consejería

Administrar Prueba Rápida de VHC (Poner alarma a 30 min.)

Cuestionario

Interpretar Prueba Rápida de VHC. Documentar el resultado. (No le diga los resultados al participante)

Continuar con el cuestionario

Post-Consejería y resultado de Prueba Rápida de VHC

Consejería de reducción de daño

Incentivo y recibo con firma

REACTIVOS AL VHC:
Prueba de confirmación de VHC en CAPASITS Juárez

REACTIVOS AL VHC:
Elegibilidad y tratamiento de VHC en CAPASITS Juárez
*Consentimiento informado del participante y pareja con presentación. La firma el participante y la entrevistadora. Se le da copia al participante, si la quiere.!
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Figure 3 University of Texas at El Paso Institutional Review Board Approval Letter
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Figure 4 Mexico Institutional Review Board Approval Letter
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Table 1 Descriptive statistics for socio-demographic characteristics, drug using and sexual risk
behaviors, other HCV risks, and HCV status among IDUs (n=49) and non-injecting sex partners
in Cd. Juarez, Mexico 2012 (n=49)

41

Table 2 Bivariate analysis of used alcohol or drugs before or during sex, unprotected vaginal or
anal sex, traumatic anal sex, and concurrent partners in the last 30 days by HCV reactivity
among non-injecting sex partners of IDUs
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